- Home
- VTYX vs RCMT Comparison
VTYX vs RCMT Comparison
Compare VTYX & RCMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- RCMT
- Stock Information
- Founded
- VTYX 2018
- RCMT 1971
- Country
- VTYX United States
- RCMT United States
- Employees
- VTYX N/A
- RCMT N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- RCMT Professional Services
- Sector
- VTYX Health Care
- RCMT Consumer Discretionary
- Exchange
- VTYX Nasdaq
- RCMT Nasdaq
- Market Cap
- VTYX 154.9M
- RCMT 172.2M
- IPO Year
- VTYX 2021
- RCMT N/A
- Fundamental
- Price
- VTYX $2.58
- RCMT $23.56
- Analyst Decision
- VTYX Buy
- RCMT Strong Buy
- Analyst Count
- VTYX 4
- RCMT 2
- Target Price
- VTYX $11.33
- RCMT $33.50
- AVG Volume (30 Days)
- VTYX 1.1M
- RCMT 45.5K
- Earning Date
- VTYX 08-15-2025
- RCMT 08-06-2025
- Dividend Yield
- VTYX N/A
- RCMT N/A
- EPS Growth
- VTYX N/A
- RCMT N/A
- EPS
- VTYX N/A
- RCMT 1.74
- Revenue
- VTYX N/A
- RCMT $290,914,000.00
- Revenue This Year
- VTYX N/A
- RCMT $16.29
- Revenue Next Year
- VTYX N/A
- RCMT $6.16
- P/E Ratio
- VTYX N/A
- RCMT $13.59
- Revenue Growth
- VTYX N/A
- RCMT 8.53
- 52 Week Low
- VTYX $0.78
- RCMT $13.18
- 52 Week High
- VTYX $3.39
- RCMT $27.24
- Technical
- Relative Strength Index (RSI)
- VTYX 46.35
- RCMT 40.83
- Support Level
- VTYX $2.63
- RCMT $23.10
- Resistance Level
- VTYX $2.92
- RCMT $24.19
- Average True Range (ATR)
- VTYX 0.22
- RCMT 0.90
- MACD
- VTYX -0.08
- RCMT -0.34
- Stochastic Oscillator
- VTYX 0.00
- RCMT 21.85
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About RCMT RCM Technologies Inc.
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.